Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation.

Dehlin M, Andersson S, Erlandsson M, Brisslert M, Bokarewa M.

J Leukoc Biol. 2011 Oct;90(4):811-7. doi: 10.1189/jlb.1110640. Epub 2011 Jul 19.

PMID:
21771900
2.

Fms-like tyrosine kinase 3 ligand controls formation of regulatory T cells in autoimmune arthritis.

Svensson MN, Andersson SE, Erlandsson MC, Jonsson IM, Ekwall AK, Andersson KM, Nilsson A, Bian L, Brisslert M, Bokarewa MI.

PLoS One. 2013;8(1):e54884. doi: 10.1371/journal.pone.0054884. Epub 2013 Jan 21.

3.

Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.

Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenen-de Roo CJ, Heinegård D, van den Berg WB.

Arthritis Res. 1999;1(1):81-91. Epub 1999 Oct 26.

4.

Neuromodulation of synovitis: capsaicin effect on severity of experimental arthritis.

Inman RD, Chiu B, Rabinovich S, Marshall W.

J Neuroimmunol. 1989 Sep;24(1-2):17-22.

PMID:
2808684
5.

Impaired signaling through the Fms-like tyrosine kinase 3 receptor increases osteoclast formation and bone damage in arthritis.

Svensson MN, Erlandsson MC, Jonsson IM, Andersson KM, Bokarewa MI.

J Leukoc Biol. 2016 Mar;99(3):413-23. doi: 10.1189/jlb.3HI1114-572RR. Epub 2015 Sep 21.

6.

c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.

Paniagua RT, Chang A, Mariano MM, Stein EA, Wang Q, Lindstrom TM, Sharpe O, Roscow C, Ho PP, Lee DM, Robinson WH.

Arthritis Res Ther. 2010;12(1):R32. doi: 10.1186/ar2940. Epub 2010 Feb 24.

7.

Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis.

Andersson SE, Svensson MN, Erlandsson MC, Dehlin M, Andersson KM, Bokarewa MI.

PLoS One. 2012;7(10):e47668. doi: 10.1371/journal.pone.0047668. Epub 2012 Oct 17.

8.

SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis.

Madan B, Goh KC, Hart S, William AD, Jayaraman R, Ethirajulu K, Dymock BW, Wood JM.

J Immunol. 2012 Oct 15;189(8):4123-34. doi: 10.4049/jimmunol.1200675. Epub 2012 Sep 7.

9.

Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis.

Mould AW, Tonks ID, Cahill MM, Pettit AR, Thomas R, Hayward NK, Kay GF.

Arthritis Rheum. 2003 Sep;48(9):2660-9.

10.

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.

Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T, Mosse C, Pardoll DM, Small D.

Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16741-6. Epub 2005 Nov 4.

11.

Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints.

Angyal A, Egelston C, Kobezda T, Olasz K, László A, Glant TT, Mikecz K.

Arthritis Res Ther. 2010;12(2):R44. doi: 10.1186/ar2954. Epub 2010 Mar 18.

12.
13.

Joint production of IL-22 participates in the initial phase of antigen-induced arthritis through IL-1β production.

Pinto LG, Talbot J, Peres RS, Franca RF, Ferreira SH, Ryffel B, Aves-Filho JC, Figueiredo F, Cunha TM, Cunha FQ.

Arthritis Res Ther. 2015 Sep 2;17:235. doi: 10.1186/s13075-015-0759-2.

14.

Activation of cannabinoid receptor 2 attenuates synovitis and joint distruction in collagen-induced arthritis.

Gui H, Liu X, Liu LR, Su DF, Dai SM.

Immunobiology. 2015 Jun;220(6):817-22. doi: 10.1016/j.imbio.2014.12.012. Epub 2014 Dec 30.

PMID:
25601571
15.

Bone- and cartilage-protective effects of a monoclonal antibody against colony-stimulating factor 1 receptor in experimental arthritis.

Toh ML, Bonnefoy JY, Accart N, Cochin S, Pohle S, Haegel H, De Meyer M, Zemmour C, Preville X, Guillen C, Thioudellet C, Ancian P, Lux A, Sehnert B, Nimmerjahn F, Voll RE, Schett G.

Arthritis Rheumatol. 2014 Nov;66(11):2989-3000. doi: 10.1002/art.38624.

16.

Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor.

Conway JG, Wakefield JA, Brown RH, Marron BE, Sekut L, Stimpson SA, McElroy A, Menius JA, Jeffreys JJ, Clark RL, et al.

J Exp Med. 1995 Aug 1;182(2):449-57.

17.

Effects of antibody to receptor activator of nuclear factor κ-B ligand on inflammation and cartilage degradation in collagen antibody-induced arthritis in mice.

Funato S, Matsunaga A, Oh K, Miyamoto Y, Yoshimura K, Tanaka J, Suzuki D, Uyama R, Suzuki H, Mishima K, Nakamura M, Namiki O, Baba K, Inagaki K, Kamijo R.

J Negat Results Biomed. 2014 Dec 12;13:18. doi: 10.1186/s12952-014-0018-0.

18.

Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts.

Yamamoto A, Fukuda A, Seto H, Miyazaki T, Kadono Y, Sawada Y, Nakamura I, Katagiri H, Asano T, Tanaka Y, Oda H, Nakamura K, Tanaka S.

Arthritis Rheum. 2003 Sep;48(9):2682-92.

19.

Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.

Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB.

Arthritis Rheum. 2004 Feb;50(2):650-9.

20.

Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.

Cejka D, Hayer S, Niederreiter B, Sieghart W, Fuereder T, Zwerina J, Schett G.

Arthritis Rheum. 2010 Aug;62(8):2294-302. doi: 10.1002/art.27504.

Supplemental Content

Support Center